226:. (2012) This was the second part of a task that a group of researchers including Dalbeth that was asked to complete for the American College of Rheumatology (ACR) to develop nonpharmacologic and pharmacologic guidelines for safe and effective treatments in gout. After completing a review of the literature and conducting formal group assessments, they completed the "first ACR guidelines for the therapy and anti-inflammatory prophylaxis of acute gout attacks."
186:
220:. The evidence suggested that further studies would be helpful, concluding it was "hoped that publication of these guidelines, along with effective patient education in gout treatments, and the objectives and safety issues of management, will improve patient adherence, quality of care, and outcomes in management of gout."
133:
challenges widely-held beliefs about the risk factors and causes of the condition. Her work confirms that there are many factors determining gout, but concludes that most people, including some health professionals, view it as a "self-inflicted condition for which dietary solutions are most important
141:
That there are disparities in gout care in
Indigenous people is without a doubt. The challenge for healthcare providers in every country, including Aotearoa New Zealand, is to authentically partner with Indigenous people to develop culturally appropriate, acceptable and effective systems to overcome
116:
Dalbeth is a principal investigator in the
Auckland Bone and Joint Research Group, and a member of the medical committee for the Auckland Medical Research Foundation. She is co-chair of the Calcium pyrophosphate deposition (CPPD) Working Group, (OMERACT), and was part of the Core Leadership Team for
154:
A paper published in 2021 summarising research that
Dalbeth had been involved in, concluded that there was the existence of population-amplified genetic variants conferring risk of gout in Polynesian populations. Dalbeth collaborated on a 2020 study that did a content analysis of visual images used
155:
in educational resources about Gout and from the data, the researchers concluded: "Key concepts about gout and treatment are underrepresented in the images used in educational resources for patients. A large proportion of the images do not convey useful information about gout or its management."
146:
A review of the effectiveness of interventions to improve uptake of urate-lowering therapy (URL) in patients with gout in 2020 noted, in the paper co-edited by
Dalbeth, that globally low numbers of patients were being treated with ULT was low. The researchers concluded for this to improve there
170:
In 2021 Dalbeth won the top research award of the medical faculty of the
University of Auckland, the Gluckman Medal, for distinguished contribution to research on gout. Professor John Fraser, the Dean of the Faculty of Medical and Health Science said
113:, Dalbeth returned to Auckland in 2005 and to take up dual appointments as professor at the University of Auckland and at Auckland District Health Board. In 2016, she was chair of The Health & Safety Commission's expert advisory group on gout.
150:
may be because they involve the most patient engagement, empowering patients to share decisions about their care, which increases the likelihood that they will make the sustained behavioural changes required to take long-term medication."
362:
174:
Nicola's research has contributed to dispelling the many myths about gout and her findings have been instrumental in improving the treatments available for patients with this debilitating disease."
137:
In 2021 in response to data that showed gout disproportionally affects MÄori, Dalbeth co-authored a research paper that reviewed inequities in health due to gout management. The paper concluded:
232:. (2015) Dalbeth was a member of an international group of researchers that did a review of the literature on advanced imaging of gout that provided data to develop the classification criteria.
117:
2020 American
College of Rheumatology Guideline for the Management of Gout. Dalbeth is an Associate Investigator at the Maurice Wilkins Centre for Molecular Biodiscovery, and a Consultant for
875:
849:
617:
105:
Dalbeth completed undergraduate medical training at Otago
Medical School in 1995 and rheumatology advanced training in Auckland in 2002. After postgraduate research training at the
1246:
1256:
419:
142:
disparities and enable a pathway to health equity and beyond for people with gout. To fail to do so is acceptance of the status quo, and is, by definition, structural racism.
97:
and laboratory research programmes and holds dual appointments as a full professor at the
University of Auckland and as a consultant for the Auckland District Health Board.
354:
933:"2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia"
528:
389:
210:
American
College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
561:
147:
needed to be a greater patient understanding of the process to get adherence to the therapy, and that nurse-led interventions were often the most effective,
164:
906:
1251:
993:"2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis"
212:(2012) This is part 1 of research by a team including Dalbeth, to develop recommendations for effective treatment of gout specifically focusing on
167:
in 2019, an "honour that recognises distinction in research, scholarship or the advancement of knowledge at the highest international standards."
1041:
591:
871:
613:
302:
224:
American
College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis
1194:"Dose Adjustment of Allopurinol According to Creatinine Clearance Does not Provide Adequate Control of Hyperuricemia in Patients with GoutD"
1266:
1236:
790:
258:
Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
1108:
1241:
1261:
1208:
1060:"2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative"
230:
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
763:"Aotearoa New Zealand MÄori and Pacific population-specific gout risk variants: CLNK is a separate risk gene at the SLC2A9 locus"
739:
272:......further work is required to clarify the safety and efficacy of allopurinol dose escalation, particularly in patients with
332:
519:
118:
1130:"CD56brightNK Cells Are Enriched at Inflammatory Sites and Can Engage with Monocytes in a Reciprocal Program of Activation"
236:
CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation.
1175:
265:
385:
446:
553:
814:"Not Every Picture Tells a Story: A Content Analysis of Visual Images in Patient Educational Resources About Gout"
898:
110:
1231:
67:
247:
992:
694:"Interventions to improve uptake of urate-lowering therapy in patients with gout: a systematic review"
583:
251:
106:
294:
42:
195:
1167:
841:
812:
Krasnoryadtseva, Alina; Derksen, Christina; Dalbeth, Nicola; Petrie, Keith J. (1 December 2020).
782:
762:
246:, suggesting that "this interaction is important in the maintenance of inflammation in chronic
1159:
1151:
1100:
1082:
1059:
1033:
1015:
970:
952:
833:
731:
713:
674:
645:"Inequities in people with gout: a focus on MÄori (Indigenous People) of Aotearoa New Zealand"
501:
238:(2004) This paper, co-authored by Dalbeth, recorded the findings of research into the role of
94:
134:
and effective, despite no clinical trial data in people with gout to support this approach."
1141:
1090:
1074:
1023:
1007:
960:
944:
825:
774:
721:
705:
664:
656:
491:
481:
273:
1193:
411:
242:
at sites of inflammation. The study showed that NK cells are capable of interacting with
217:
692:
Gill, Iqbal; Dalbeth, Nicola; 'Ofanoa, Malakai; Goodyear-Smith, Felicity (7 July 2020).
191:
1095:
1028:
965:
932:
726:
669:
644:
496:
469:
1225:
845:
786:
693:
470:"OMERACT: An international initiative to improve outcome measurement in rheumatology"
269:
1171:
1078:
1058:
Neogi, Tuhina; Jansen, Tim L Th A; Dalbeth, Nicola; et al. (9 September 2015).
614:"Nicola Dalbeth and Keith J Petrie: It's time to change the name of gout - The BMJ"
324:
239:
86:
1146:
261:
1129:
709:
660:
640:
1155:
1086:
1019:
956:
897:
Health and medicine, Faculty of Medical and Health Sciences (27 April 2021).
717:
813:
243:
213:
1163:
1104:
1037:
974:
837:
735:
678:
505:
486:
442:
829:
778:
521:
2020 American College of Rheumatology Guideline for the Management of Gout
899:"World-leading gout expert Professor Nicola Dalbeth wins Gluckman Medal"
872:"Researchers and scholars at the top of their fields elected as Fellows"
1011:
948:
931:
Khanna, Dinesh; Fitzgerald, John D.; et al. (28 September 2012).
89:
whose research focuses on understanding the impact and mechanisms of
268:......investigated whether such dosing provides adequate control of
991:
Khanna, Dinesh; Khanna, Puja P.; et al. (28 September 2012).
443:"About the Calcium pyrophosphate deposition (CPPD) Working Group"
704:(3). Royal College of General Practitioners: bjgpopen20X101051.
130:
90:
926:
924:
1140:(10). The American Association of Immunologists: 6418ā6426.
355:"Men, MÄori and Pacific people need better gout medication"
1187:
1185:
986:
984:
260:(2006) After examining the guidelines stating that "
63:
55:
38:
30:
23:
1128:Dalbeth, Nicola; et al. (4 November 2004).
590:. Auckland District Health Board Te Toka Tumai.
525:(Supplementary Appendix 2: Panel/Teams Involved)
468:Tugwell, Peter; et al. (26 November 2007).
874:. Royal Society Te ApÄrangi. 21 November 2019.
649:Therapeutic Advances in Musculoskeletal Disease
8:
1247:Academic staff of the University of Auckland
1123:
1121:
295:"Professor Nicola Dalbeth, MBChB, MD, FRACP"
59:Research into diagnosis and management gout
1257:Fellows of the Royal Society of New Zealand
129:Much of Dalbeth's research that focuses on
165:Fellow of the Royal Society of New Zealand
20:
16:Rheumatologist and academic in New Zealand
1145:
1094:
1027:
964:
725:
668:
495:
485:
761:Ji, Aichang; et al. (1 July 2021).
384:Faculty of Medical and Health Sciences.
286:
264:doses should be adjusted according to
1192:Dalbeth, Nicola; et al. (2006).
878:from the original on 28 December 2019
852:from the original on 28 December 2019
554:"Our People: Associate Investigators"
7:
584:"Auckland DHB Rheumatology Services"
416:Auckland Medical Research Foundation
392:from the original on 4 February 2022
1047:from the original on 28 March 2016.
639:Te Karu, Leanne; Dalbeth, Nicoloa;
1214:from the original on 8 April 2022.
909:from the original on 28 April 2021
742:from the original on 18 March 2022
14:
1178:from the original on 26 May 2021.
1114:from the original on 6 July 2017.
793:from the original on 14 July 2021
620:from the original on 12 July 2021
594:from the original on 6 March 2022
564:from the original on 13 July 2021
534:from the original on 14 July 2021
449:from the original on 13 July 2021
422:from the original on 8 April 2022
365:from the original on 8 April 2022
335:from the original on 12 July 2021
305:from the original on 7 April 2022
1067:Annals of the Rheumatic Diseases
184:
1252:New Zealand medical researchers
1079:10.1136/annrheumdis-2015-208237
386:"Bone and Joint Research Group"
325:"Dr Nicola Dalbeth Healthpoint"
388:. The University of Auckland.
119:Auckland District Health Board
1:
1000:Arthritis Care & Research
937:Arthritis Care & Research
1147:10.4049/jimmunol.173.10.6418
1267:New Zealand rheumatologists
1237:New Zealand women academics
1201:The Journal of Rheumatology
818:The Journal of Rheumatology
767:The Journal of Rheumatology
1283:
1242:University of Otago alumni
903:The University of Auckland
85:is a New Zealand academic
1262:New Zealand women writers
1134:The Journal of Immunology
710:10.3399/bjgpopen20x101051
661:10.1177/1759720X211028007
73:
48:
1006:(10). Wiley: 1447ā1461.
943:(10). Wiley: 1431ā1446.
412:"Our Medical Committee"
121:Rheumatology Services.
111:Imperial College London
1073:(10). BMJ: 1789ā1798.
558:Maurice Wilkins Centre
487:10.1186/1745-6215-8-38
214:Urate-lowering therapy
163:Dalbeth was elected a
144:
68:University of Auckland
830:10.3899/jrheum.191245
779:10.3899/jrheum.201684
329:www.healthpoint.co.nz
248:inflammatory diseases
139:
266:creatinine clearance
252:rheumatoid arthritis
107:University of Oxford
101:Education and career
655:: 1759720X2110280.
616:. 5 February 2018.
361:. 29 January 2016.
43:University of Otago
216:(ULT) and chronic
194:has a profile for
159:Awards and honours
1012:10.1002/acr.21773
949:10.1002/acr.21772
824:(12): 1815ā1821.
200:
125:Selected research
77:
76:
50:Scientific career
1274:
1216:
1215:
1213:
1198:
1189:
1180:
1179:
1149:
1125:
1116:
1115:
1113:
1098:
1064:
1055:
1049:
1048:
1046:
1031:
997:
988:
979:
978:
968:
928:
919:
918:
916:
914:
894:
888:
887:
885:
883:
868:
862:
861:
859:
857:
809:
803:
802:
800:
798:
758:
752:
751:
749:
747:
729:
689:
683:
682:
672:
643:(30 June 2021).
636:
630:
629:
627:
625:
610:
604:
603:
601:
599:
580:
574:
573:
571:
569:
550:
544:
543:
541:
539:
533:
526:
516:
510:
509:
499:
489:
465:
459:
458:
456:
454:
441:Working groups.
438:
432:
431:
429:
427:
408:
402:
401:
399:
397:
381:
375:
374:
372:
370:
351:
345:
344:
342:
340:
321:
315:
314:
312:
310:
299:Gout Study Group
291:
274:renal impairment
198:
188:
187:
84:
21:
1282:
1281:
1277:
1276:
1275:
1273:
1272:
1271:
1222:
1221:
1220:
1219:
1211:
1196:
1191:
1190:
1183:
1127:
1126:
1119:
1111:
1062:
1057:
1056:
1052:
1044:
995:
990:
989:
982:
930:
929:
922:
912:
910:
896:
895:
891:
881:
879:
870:
869:
865:
855:
853:
811:
810:
806:
796:
794:
760:
759:
755:
745:
743:
691:
690:
686:
638:
637:
633:
623:
621:
612:
611:
607:
597:
595:
582:
581:
577:
567:
565:
552:
551:
547:
537:
535:
531:
524:
518:
517:
513:
467:
466:
462:
452:
450:
440:
439:
435:
425:
423:
410:
409:
405:
395:
393:
383:
382:
378:
368:
366:
359:Hutt Valley DHB
353:
352:
348:
338:
336:
323:
322:
318:
308:
306:
293:
292:
288:
283:
218:gouty arthritis
206:
205:
204:
197:Nicola Dalbeth
189:
185:
180:
161:
127:
103:
93:. She supports
82:
39:Alma mater
26:
17:
12:
11:
5:
1280:
1278:
1270:
1269:
1264:
1259:
1254:
1249:
1244:
1239:
1234:
1224:
1223:
1218:
1217:
1181:
1117:
1050:
980:
920:
889:
863:
804:
753:
684:
641:Stamp, Lisa K.
631:
605:
575:
545:
511:
460:
433:
403:
376:
346:
316:
285:
284:
282:
279:
278:
277:
255:
233:
227:
221:
190:
183:
182:
181:
179:
176:
160:
157:
126:
123:
102:
99:
87:rheumatologist
80:Nicola Dalbeth
75:
74:
71:
70:
65:
61:
60:
57:
53:
52:
46:
45:
40:
36:
35:
32:
28:
27:
25:Nicola Dalbeth
24:
15:
13:
10:
9:
6:
4:
3:
2:
1279:
1268:
1265:
1263:
1260:
1258:
1255:
1253:
1250:
1248:
1245:
1243:
1240:
1238:
1235:
1233:
1232:Living people
1230:
1229:
1227:
1210:
1206:
1202:
1195:
1188:
1186:
1182:
1177:
1173:
1169:
1165:
1161:
1157:
1153:
1148:
1143:
1139:
1135:
1131:
1124:
1122:
1118:
1110:
1106:
1102:
1097:
1092:
1088:
1084:
1080:
1076:
1072:
1068:
1061:
1054:
1051:
1043:
1039:
1035:
1030:
1025:
1021:
1017:
1013:
1009:
1005:
1001:
994:
987:
985:
981:
976:
972:
967:
962:
958:
954:
950:
946:
942:
938:
934:
927:
925:
921:
908:
904:
900:
893:
890:
877:
873:
867:
864:
851:
847:
843:
839:
835:
831:
827:
823:
819:
815:
808:
805:
792:
788:
784:
780:
776:
772:
768:
764:
757:
754:
741:
737:
733:
728:
723:
719:
715:
711:
707:
703:
699:
695:
688:
685:
680:
676:
671:
666:
662:
658:
654:
650:
646:
642:
635:
632:
619:
615:
609:
606:
593:
589:
585:
579:
576:
563:
559:
555:
549:
546:
530:
523:
522:
515:
512:
507:
503:
498:
493:
488:
483:
479:
475:
471:
464:
461:
448:
444:
437:
434:
421:
417:
413:
407:
404:
391:
387:
380:
377:
364:
360:
356:
350:
347:
334:
330:
326:
320:
317:
304:
300:
296:
290:
287:
280:
275:
271:
270:hyperuricemia
267:
263:
259:
256:
253:
249:
245:
241:
237:
234:
231:
228:
225:
222:
219:
215:
211:
208:
207:
202:
201:
193:
177:
175:
173:
168:
166:
158:
156:
152:
149:
143:
138:
135:
132:
124:
122:
120:
114:
112:
108:
100:
98:
96:
92:
88:
81:
72:
69:
66:
62:
58:
54:
51:
47:
44:
41:
37:
34:New Zealander
33:
29:
22:
19:
1204:
1200:
1137:
1133:
1070:
1066:
1053:
1003:
999:
940:
936:
911:. Retrieved
902:
892:
880:. Retrieved
866:
854:. Retrieved
821:
817:
807:
795:. Retrieved
770:
766:
756:
744:. Retrieved
701:
697:
687:
652:
648:
634:
622:. Retrieved
608:
596:. Retrieved
587:
578:
566:. Retrieved
557:
548:
536:. Retrieved
520:
514:
477:
473:
463:
451:. Retrieved
436:
424:. Retrieved
415:
406:
394:. Retrieved
379:
367:. Retrieved
358:
349:
337:. Retrieved
328:
319:
307:. Retrieved
298:
289:
257:
235:
229:
223:
209:
196:
178:Publications
172:
169:
162:
153:
148:
145:
140:
136:
128:
115:
104:
79:
78:
64:Institutions
49:
18:
445:. OMERACT.
262:allopurinol
199:(Q56192234)
31:Nationality
1226:Categories
480:(38): 38.
281:References
1156:0022-1767
1087:0003-4967
1020:2151-464X
957:2151-464X
846:212730804
787:235711900
718:2398-3795
698:BJGP Open
244:monocytes
240:(N cells)
1209:Archived
1176:Archived
1172:26744867
1164:15528382
1109:Archived
1105:26359487
1042:Archived
1038:23024029
975:23024028
907:Archived
876:Archived
850:Archived
838:32173653
791:Archived
740:Archived
736:32636201
679:34262623
618:Archived
592:Archived
562:Archived
529:Archived
527:. 2020.
506:18039364
447:Archived
420:Archived
418:. 2020.
390:Archived
363:Archived
333:Archived
303:Archived
301:. 2018.
250:such as
95:clinical
1096:4602275
1029:3662546
966:3683400
913:13 July
882:8 April
856:8 April
797:13 July
746:8 April
727:7465587
670:8252336
624:8 April
598:8 April
568:8 April
538:8 April
497:2169260
453:8 April
426:8 April
396:8 April
369:8 April
339:8 April
309:8 April
192:Scholia
1170:
1162:
1154:
1103:
1093:
1085:
1036:
1026:
1018:
973:
963:
955:
844:
836:
785:
734:
724:
716:
677:
667:
504:
494:
474:Trials
56:Fields
1212:(PDF)
1197:(PDF)
1168:S2CID
1112:(PDF)
1063:(PDF)
1045:(PDF)
996:(PDF)
842:S2CID
783:S2CID
773:(1).
532:(PDF)
83:FRSNZ
1160:PMID
1152:ISSN
1101:PMID
1083:ISSN
1034:PMID
1016:ISSN
971:PMID
953:ISSN
915:2021
884:2022
858:2022
834:PMID
799:2021
748:2022
732:PMID
714:ISSN
675:PMID
626:2022
600:2022
588:adhb
570:2022
540:2022
502:PMID
455:2022
428:2022
398:2022
371:2022
341:2022
311:2022
131:gout
109:and
91:gout
1142:doi
1138:173
1091:PMC
1075:doi
1024:PMC
1008:doi
961:PMC
945:doi
826:doi
775:doi
722:PMC
706:doi
665:PMC
657:doi
492:PMC
482:doi
1228::
1207:.
1205:33
1203:.
1199:.
1184:^
1174:.
1166:.
1158:.
1150:.
1136:.
1132:.
1120:^
1107:.
1099:.
1089:.
1081:.
1071:74
1069:.
1065:.
1040:.
1032:.
1022:.
1014:.
1004:64
1002:.
998:.
983:^
969:.
959:.
951:.
941:64
939:.
935:.
923:^
905:.
901:.
848:.
840:.
832:.
822:47
820:.
816:.
789:.
781:.
771:48
769:.
765:.
738:.
730:.
720:.
712:.
700:.
696:.
673:.
663:.
653:13
651:.
647:.
586:.
560:.
556:.
500:.
490:.
476:.
472:.
414:.
357:.
331:.
327:.
297:.
276:."
254:."
1144::
1077::
1010::
977:.
947::
917:.
886:.
860:.
828::
801:.
777::
750:.
708::
702:4
681:.
659::
628:.
602:.
572:.
542:.
508:.
484::
478:8
457:.
430:.
400:.
373:.
343:.
313:.
203:.
171:"
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.